NCT05911399 - Expanded Access Program for Tiratricol in Patients With Monocarboxylate Transporter 8 Deficiency | Biotech Hunter

Timeline

Start Date

Not specified

Conditions

Monocarboxylate Transporter 8 DeficiencyAllan-Herndon-Dudley Syndrome

Interventions

DRUG

Tiratricol

Tiratricol (3,3',5-triiodothyroacetic acid) is available as 350 µg tablets for oral administration (suspended in water and, if needed, mixed with food) or by percutaneous endoscopic gastrostomy (PEG), nasogastric or jejunal tube.

Trial Locations (15)

19104

AVAILABLE

Children's Hospital of Philadelphia, Philadelphia

30329

AVAILABLE

Children's Healthcare of Atlanta, Atlanta

32207

AVAILABLE

Nemour's Children Hospital, Jacksonville

35249

AVAILABLE

University of Alabama at Birmingham Hospital, Birmingham

38105

AVAILABLE

Le Bonheur Children's Hospital Foundation, Memphis

53326

AVAILABLE

Children's Wisconsin, Milwaukee

55101

AVAILABLE

Gillette's Children's Specialty Healthcare, Saint Paul

60611

AVAILABLE

Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago

70118

AVAILABLE

Louisiana State University Health Sciences Center and Children's Hospital, New Orleans

76106

AVAILABLE

Cook Children's Health Care System, Fort Worth

92123

AVAILABLE

Rady Children's Hospital, San Diego

97239

AVAILABLE

Oregon Health and Science University, Portland

98403

AVAILABLE

MultiCare Mary Bridge Children's Hospital, Tacoma

93636-8762

AVAILABLE

Valley Children's Hospital, Madera

01199

AVAILABLE

Baystate Medical Center, Springfield